Author(s)

Touré Moctar^*, Kouassi Kouamé K. Yvon, Séka E. Narcisse, Traoré Kady, Kimso Oumou, Niang D. Rokhaya, Odo B. Adde, Oseni Jelili, Adoubi Innocent

Department of Oncology, University Hospital of Treichville, Abidjan, Cote d’Ivoire.

In our daily practice, the use of targeted therapies (Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very few patients benefit from these therapies because of their high cost. In a cohort of 68 patients who received these therapies, a retrospective and prospective study was conducted over three years period (1 January 2013 to 31 December 2015) to evaluate their benefit in terms of quality of life, tolerance and overall survival. These targeted therapies provided a significant clinical and biological gain with acceptable toxicities (most often resolving spontaneously). Moreover, they have allowed a significant improvement in overall survival in first line metastatic treatment. The limiting factor remains their extremely high cost and therefore inaccessibility to the majority of our patients.

Cancer-Colon-Metastasis-Targeted Therapy

Moctar, T. , Yvon, K. , Narcisse, S. , Kady, T. , Oumou, K. , Rokhaya, N. , Adde, O. , Jelili, O. and Innocent, A. (2017) Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context. Journal of Cancer Therapy, 8, 785-792. doi: 10.4236/jct.2017.88068.